regadenoson has been researched along with dipyridamole in 18 studies
| Studies (regadenoson) | Trials (regadenoson) | Recent Studies (post-2010) (regadenoson) | Studies (dipyridamole) | Trials (dipyridamole) | Recent Studies (post-2010) (dipyridamole) |
|---|---|---|---|---|---|
| 321 | 53 | 264 | 7,826 | 881 | 632 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 14 (77.78) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cerqueira, MD | 1 |
| Druz, RS | 1 |
| Bengel, FM; Bravo, P; Fukushima, K; Goudarzi, B; Merrill, J | 1 |
| Abraham, MR; Abraham, TP; Bengel, FM; Bravo, PE; Merrill, J; Pinheiro, A; Pozios, I; Tsui, BM; Wahl, RL | 1 |
| Bateman, TM; Case, JA; Courter, SA; Cullom, SJ; McGhie, AI | 1 |
| Boulanger, L; Friedman, M; Gatt, E; Kothari, S; Spalding, J; Wu, Y | 1 |
| Breeze, J; Hudgens, S; Spalding, J | 1 |
| Arai, AE; Bandettini, WP; Booker, OJ; Hsu, LY; Kellman, P; Leung, S; Mancini, C; Shanbhag, SM; Vasu, S; Wilson, J | 1 |
| Bremerich, J; Kawel-Boehm, N | 1 |
| Gould, KL; Johnson, NP | 1 |
| Dilsizian, V; Narula, J | 1 |
| Amer, KA; Cohen, G; Edwin, SB; Hurren, JR | 1 |
| Babar, AK; Bui, L; DeGolovine, A; Gould, KL; Johnson, NP; Kitkungvan, D; Kumar, S; Madjid, M; Nacimbene, A; Patel, MB; Roby, AE; Vejpongsa, P | 1 |
| Al Badarin, F; Bateman, TM; Case, JA; Chan, PS; Courter, S; Heller, GV; Kennedy, KF; McGhie, AI; Patel, KK; Spertus, JA | 1 |
| Ahmed, A; Ahmed, D; Al-Mallah, M; Alali Alfaris, M; Alharthi, M; Aljizeeri, A; Alsaileek, A; Elneama, A; Farea, J; Suliman, I | 1 |
| Angoulvant, D; Bailly, M; Brana, Q; Courtehoux, M; Metrard, G; Ribeiro, MJ; Thibault, F | 1 |
| Carafa, MRP; Flammia, FC; Larici, AR; Lo Piccolo, F; Marano, R; Meduri, A; Merlino, B; Natale, L; Rovere, G; Savino, G | 1 |
5 review(s) available for regadenoson and dipyridamole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in pharmacologic agents in imaging: new A2A receptor agonists.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Coronary Vessels; Cyclohexanecarboxylic Acids; Dipyridamole; Heart; Humans; Organotechnetium Compounds; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2006 |
Current advances in vasodilator pharmacological stress perfusion imaging.
Topics: Adenosine; Adult; Contraindications; Coronary Artery Disease; Dipyridamole; Exercise Test; Female; Humans; Myocardial Perfusion Imaging; Purines; Pyrazoles; Radiopharmaceuticals; Vasodilator Agents | 2009 |
Magnetic resonance stress imaging of myocardial perfusion and wall motion.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Cardiotonic Agents; Coronary Angiography; Dipyridamole; Exercise Test; Humans; Magnetic Resonance Imaging; Myocardial Perfusion Imaging; Purines; Pyrazoles; Vasodilator Agents | 2014 |
Practical instructions for using drugs in CT and MR cardiac imaging.
Topics: Adenosine; Adrenergic beta-Antagonists; Anti-Anxiety Agents; Atropine; Calcium Channel Blockers; Cardiac Imaging Techniques; Computed Tomography Angiography; Contraindications, Drug; Coronary Angiography; Coronary Vessels; Dipyridamole; Dobutamine; Heart; Humans; Ivabradine; Magnetic Resonance Imaging; Nitroglycerin; Purines; Pyrazoles; Vasodilator Agents | 2021 |
2 trial(s) available for regadenoson and dipyridamole
| Article | Year |
|---|---|
Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Caffeine; Cardiovascular Diseases; Coronary Circulation; Dipyridamole; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purines; Pyrazoles | 2019 |
Randomized Comparison of Clinical Effectiveness of Pharmacologic SPECT and PET MPI in Symptomatic CAD Patients.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Agents; Comparative Effectiveness Research; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Stenosis; Dipyridamole; Female; Health Status; Humans; Kansas; Male; Middle Aged; Myocardial Perfusion Imaging; Myocardial Revascularization; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prospective Studies; Purines; Pyrazoles; Referral and Consultation; Severity of Illness Index; Single Photon Emission Computed Tomography Computed Tomography; Time Factors; Treatment Outcome; Vasodilator Agents | 2019 |
11 other study(ies) available for regadenoson and dipyridamole
| Article | Year |
|---|---|
Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.
Topics: Coronary Circulation; Dipyridamole; Female; Hemodynamics; Humans; Injections; Male; Middle Aged; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purinergic P1 Receptor Agonists; Purines; Pyrazoles; Retrospective Studies; Rubidium Radioisotopes; Stress, Physiological | 2011 |
Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy.
Topics: Adenosine A2 Receptor Antagonists; Cardiomyopathy, Hypertrophic; Coronary Circulation; Dipyridamole; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Positron-Emission Tomography; Purines; Pyrazoles; Reproducibility of Results; Retrospective Studies; ROC Curve; Severity of Illness Index; Stroke Volume; Vasodilator Agents | 2012 |
Regadenoson pharmacologic rubidium-82 PET: a comparison of quantitative perfusion and function to dipyridamole.
Topics: Aged; Blood Pressure; Body Mass Index; Chlorides; Dipyridamole; Exercise Test; Female; Hemodynamics; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Myocardial Perfusion Imaging; Perfusion; Positron-Emission Tomography; Purines; Pyrazoles; Radiopharmaceuticals; Rubidium; Rubidium Radioisotopes; Ventricular Function, Left | 2013 |
Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole.
Topics: Adenosine; Coronary Artery Disease; Data Collection; Dipyridamole; Health Personnel; Humans; Myocardial Perfusion Imaging; Nuclear Medicine Department, Hospital; Purines; Pyrazoles; Receptor, Adenosine A2A; Time Factors; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
Patient- and clinician-reported satisfaction with pharmacological stress agents for single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI).
Topics: Adenosine A2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Dipyridamole; Female; Humans; Male; Medical Staff, Hospital; Middle Aged; Myocardial Perfusion Imaging; Outcome Assessment, Health Care; Patient Satisfaction; Purines; Pyrazoles; Self Report; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance.
Topics: Adenosine; Coronary Circulation; Dipyridamole; Female; Healthy Volunteers; Heart Rate; Humans; Infusions, Parenteral; Magnetic Resonance Imaging; Male; Myocardial Perfusion Imaging; Predictive Value of Tests; Purines; Pyrazoles; Vasodilation; Vasodilator Agents; Young Adult | 2013 |
Regadenoson versus dipyridamole hyperemia for cardiac PET imaging.
Topics: Adenosine A2 Receptor Agonists; Adult; Aged; Dipyridamole; Female; Heart Diseases; Hemodynamics; Humans; Hyperemia; Male; Middle Aged; Positron-Emission Tomography; Purines; Pyrazoles; Vasodilator Agents | 2015 |
Capturing maximal coronary vasodilation for myocardial perfusion imaging: is timing everything?
Topics: Adenosine A2 Receptor Agonists; Dipyridamole; Humans; Hyperemia; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purines; Pyrazoles; Sensitivity and Specificity; Time Factors; Tomography, Emission-Computed, Single-Photon; Vasodilation; Vasodilator Agents | 2015 |
Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
Topics: Adenosine A2 Receptor Agonists; Aged; Cohort Studies; Cost-Benefit Analysis; Dipyridamole; Dyspnea; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Retrospective Studies; Vasodilator Agents | 2017 |
Are Patients With End-Stage Liver Disease Maximally Vasodilated?: Insights From Rubidium-82 PET Dilatory Perfusion.
Topics: Aged; Coronary Artery Disease; Dipyridamole; End Stage Liver Disease; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Purines; Pyrazoles; Radiopharmaceuticals; Retrospective Studies; Rubidium Radioisotopes; Vasodilation; Vasodilator Agents | 2019 |
Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera.
Topics: Coronary Circulation; Dipyridamole; Humans; Hyperemia; Myocardial Perfusion Imaging; Purines; Pyrazoles; Retrospective Studies; Tomography, Emission-Computed, Single-Photon | 2022 |